BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2019 8:06:40 AM | Browse: 746 | Download: 1100
 |
Received |
|
2019-02-27 05:56 |
|
Peer-Review Started |
|
2019-02-27 12:08 |
|
To Make the First Decision |
|
2019-04-12 00:46 |
|
Return for Revision |
|
2019-04-24 09:24 |
|
Revised |
|
2019-07-19 22:32 |
|
Second Decision |
|
2019-08-29 00:34 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-09-05 17:43 |
|
Articles in Press |
|
2019-09-05 17:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-10-23 07:09 |
|
Publish the Manuscript Online |
|
2019-10-25 08:06 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Manreet Randhawa, Gregory Gaughran, Christine Archer, Paul Pavli, Adrienne Morey, Sayed Ali and Desmond Yip |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Desmond Yip, FRACP, MBBS, Associate Professor, Doctor, Doctor, Professor, Senior Lecturer, Department of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, Yamba Drive, Garran, ACT, ANU Medical School, Australian National University, Acton, ACT, Canberra 2605, Australia. desmond.yip@act.gov.au |
| Key Words |
Ipilimumab; Nivolumab; Metastatic melanoma; Steroid-refractory colitis; Infliximab-refractory colitis; Vedolizumab |
| Core Tip |
Dual checkpoint inhibition improves response rates in treatment naïve patients with metastatic melanoma compared to monotherapy. However, it confers a higher rate of toxicity, including immune-related colitis. The use of vedolizumab, a humanized monoclonal antibody against 47 integrin has proven effective in cases refractory to standard treatment. This is a case report of a 27-year-old female with Stage IVd metastatic melanoma treated with ipilimumab and nivolumab. She developed severe colitis refractory to methylprednisolone, infliximab and mycophenolate mofetil but responded to vedolizumab. This supports its use in severe immune related colitis refractory to standard immunosuppression. |
| Publish Date |
2019-10-25 08:06 |
| Citation |
Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World J Clin Oncol 2019; 10(9): 350-357 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i10/350.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i10.350 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
